KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Asset Writedowns and Impairment (2016 - 2025)

Neogenomics filings provide 12 years of Asset Writedowns and Impairment readings, the most recent being $7.1 million for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $7.1 million in Q3 2025 year-over-year; TTM through Dec 2025 was $15.3 million, a 2269.92% increase, with the full-year FY2024 number at $500000.0, down 70.59% from a year prior.
  • Asset Writedowns and Impairment hit $7.1 million in Q3 2025 for Neogenomics, down from $8.2 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $8.2 million in Q2 2025 to a low of -$3000.0 in Q4 2023.
  • Median Asset Writedowns and Impairment over the past 4 years was $718000.0 (2022), compared with a mean of $2.0 million.
  • Biggest five-year swings in Asset Writedowns and Impairment: tumbled 100.42% in 2023 and later skyrocketed 16766.67% in 2024.
  • Neogenomics' Asset Writedowns and Impairment stood at $718000.0 in 2022, then tumbled by 100.42% to -$3000.0 in 2023, then skyrocketed by 16766.67% to $500000.0 in 2024, then skyrocketed by 1317.2% to $7.1 million in 2025.
  • The last three reported values for Asset Writedowns and Impairment were $7.1 million (Q3 2025), $8.2 million (Q2 2025), and $500000.0 (Q4 2024) per Business Quant data.